EndPoint and SmartAction partner to automate Pharma/ Biotech services
SmartAction and EndPoint Technologies have formed a strategic partnership to expand the availability of AI-powered customer technology.
List view / Grid view
News
Lab Innovations – back for 2017!
Lab Innovations – the UK’s only dedicated showcase for laboratory technology, analytical and biotech equipment – returns for its sixth consecutive year on 1 & 2 November 2017 at the NEC, Birmingham...
Precision NanoSystems at the BIO International Convention 2017
A key session opens up the challenges of delivering personalized genetic medicines...
Valeant announces sale of iNova Pharmaceuticals for $930 million
Valeant Pharmaceuticals has entered into an agreement to sell its iNova Pharmaceuticals business for $930 million in cash.
BIA report shows UK on track to be world’s third global biotech cluster
A new report released by the UK BioIndustry Association (BIA) shows that the UK maintained its strong leadership position in European biotech funding last year and has the strongest pipeline in Europe for future drug development.
Collaboration is ‘game changer’ in delivering cell and gene therapies
Collaboration between the pharmaceutical industry, patients and health regulators will be a ‘game changer’ in delivering exciting new cell and gene therapies to treat conditions like cancer and vision loss.
FDA approves BioMarin’s manufacturing facility in Cork, Ireland
The FDA has approved BioMarin Pharmaceutical’s bulk biologics manufacturing plant, located in Cork, Ireland for production of the formulated bulk substance.
Initial successes in treating a hitherto incurable liver disorder
Primary sclerosing cholangitis is a currently incurable liver disorder, primarily affecting younger adults aged between 30 and 40.
Is the finger-stick blood test necessary for type 2 diabetes treatment?
In the first large pragmatic trial of its kind in the United States, results from a study show that checking finger-stick blood sugars may not help diabetes patients who do not use insulin.
SMC rejects Perjeta (pertuzumab) for NHS use for breast cancer
The Scottish Medicines Consortium (SMC) has made a final decision to turn down Perjeta (pertuzumab) for routine NHS funding for first line use in women whose HER2-positive breast cancer has returned to the breast but is inoperable, or where it has spread to other parts of the body.
Health leaders launch Alliance for Transparent & Affordable Prescriptions
Health leaders announced the launch of the Alliance for Transparent & Affordable Prescriptions (ATAP), a coalition of provider and patient groups concerned about the practices of pharmacy benefit managers (PBMs) driving up drug costs.
Pfizer and Lilly receive FDA fast track designation for tanezumab
The FDA has granted fast track designation for Pfizer and Eli Lilly’s tanezumab for the treatment of chronic pain in patients with osteoarthritis...
Gilead submits drug application to FDA for HIV treatment
Gilead has submitted a new drug application to the US FDA for treatments of HIV.
NICE recommends Lilly’s Olaratumab (Lartruvo) to treat sarcoma
Olaratumab is the first monoclonal antibody, in combination with doxorubicin, to be recommended for the treatment of advanced soft tissue sarcoma.
Scotland approves Ipsen’s cabozantinib to treat kidney cancer
The SMC endorses routine prescribing across NHS Scotland of Ipsen’s cabozantinib, offering a new therapy option to help battle kidney cancer.
